Related Experiment Videos
Congenital cutaneous candidiasis--report of two cases
F C Hung1, C B Huang, S C Huang
1Department of Pediatrics, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
Abstract:
Candida infection contracted in utero and manifested at birth is a rare event. Two newborn infants are presented with generalized maculopapular rashes at birth. The eruption soon became vesicles or pustules; no other manifestations were found. Candida albicans was isolated from the skin lesion. After topical antifungal application, the lesions became fine and desquamated in the recuperative period. No complication was noted during the course. The diagnosis of congenital cutaneous candidiasis relies on its clinical course and positive culture result of the skin lesion. No systemic antifungal therapy is recommended except for the high risk infants.
Insights
Congenital cutaneous candidiasis is a rare newborn infection presenting as skin rashes. Topical antifungal treatment is effective, with systemic therapy reserved for high-risk infants.
Area of Science:
- Neonatal dermatology
- Infectious diseases
- Mycology
Background:
- Congenital cutaneous candidiasis is a rare manifestation of Candida infection acquired in utero.
- It presents shortly after birth with characteristic skin lesions.
Observation:
- Two neonates presented with generalized maculopapular rashes at birth, progressing to vesicles or pustules.
- Candida albicans was identified as the causative agent from skin lesions.
- No other systemic manifestations were observed in the affected infants.
Findings:
- Topical antifungal treatment led to lesion resolution, characterized by fine desquamation during recovery.
- The clinical course and positive culture confirmed the diagnosis.
- No complications arose during the infants' recovery period.
Implications:
- Diagnosis relies on clinical presentation and laboratory confirmation of Candida albicans.
- Systemic antifungal therapy is generally not required for uncomplicated cases.
- Topical treatment is sufficient for most infants with congenital cutaneous candidiasis, reserving systemic options for high-risk neonates.